The premise behind this grant application is that impeccable characterization and understanding of a systemically administered new antineoplastic agent's pharmacology and effect on molecular targets in cancer should allow better clinical utilization of that agent. Determination of clinical toxicities and maximum tolerated dose (MTD) of an agent is no longer sufficient. Ideally, early clinical trials of an investigational agent should define pharmacokinetic (PK) disposition and metabolism, with correlation to pharmacodynamic (PD) manifestations at molecular, cellular, and clinical levels. With this abiding philosophy and hypothesis, performance of scientifically directed phase I trials of promising novel anti-cancer agents available through the National Cancer Institute is warranted. Integrating information regarding the mechanism of action and effect on molecular targets with development of biomarkers in phase I trials is the strategy that will be pursued with the following objectives to : define the toxicities of new antineoplastic agents in patients with advanced cancer;re-define (as necessary)the toxicities and PK of existing anticancer agents administered in combination with molecularly targeted agents, colony stimulating factors and other toxicity-ameliorating agents that may facilitate the exploration of more effective doses and schedules;provide information on the absorption, distribution, metabolism, and elimination of antitumor agents;define treatment regimens for use in phase II trials;establish, based on clinical and pharmacologic characteristics, appropriate phase II doses in special patient populations (e.g., patients with impaired organ function;heavily pretreated patients or geriatric patient populations), explore PK and PD differences based on sex, race, or ethnic group;obtain preliminary information on PK/PD correlations that can then be extended in phase II trials;incorporate basic laboratory and correlative science studies, when possible and appropriate, to enhance the understanding of the biochemical and/or biological mechanisms of drug actions;study the PK and the PD impact of drugs on specific metabolic pathways and molecular targets using non-invasive techniques such as magnetic resonance spectroscopy and nuclear imaging with radio-labeled drugs;and integrate pharmacogenomic studies to characterize differences in relevant drug metabolizing enzymes and drug targets related to toxicity and efficacy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA099168-10
Application #
8234199
Study Section
Special Emphasis Panel (ZCA1-SRRB-K (O1))
Program Officer
Ivy, S Percy
Project Start
2003-03-18
Project End
2014-02-28
Budget Start
2012-04-24
Budget End
2014-02-28
Support Year
10
Fiscal Year
2012
Total Cost
$255,617
Indirect Cost
$86,893
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Lee, James J; Chu, Edward (2018) The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More? Oncology (Williston Park) 32:437-42, 444
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2017) A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clin Cancer Res 23:697-706
Stoller, Ronald; Schmitz, John C; Ding, Fei et al. (2017) Phase I study of veliparib in combination with gemcitabine. Cancer Chemother Pharmacol 80:631-643
Bodugam, Mahipal; Javed, Salim; Ganguly, Arghya et al. (2016) A Pot-Economical Approach to the Total Synthesis of Sch-725674. Org Lett 18:516-9
Beumer, Jan H; Ding, Fei; Tawbi, Hussein et al. (2016) Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol 34:110-6
Beumer, Jan H; Tawbi, Hussein; Ivy, S Percy (2016) Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. J Clin Oncol 34:2430-1
Villaruz, Liza C; Jones, Helen; Dacic, Sanja et al. (2016) ATM protein is deficient in over 40% of lung adenocarcinomas. Oncotarget 7:57714-57725
Appleman, Leonard J; Balasubramaniam, Sanjeeve; Parise, Robert A et al. (2015) A phase i study of DMS612, a novel bifunctional alkylating agent. Clin Cancer Res 21:721-9
Newman, Edward M; Morgan, Robert J; Kummar, Shivaani et al. (2015) A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol 75:537-46

Showing the most recent 10 out of 58 publications